# Shenzhen TargetRx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-targetrx

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.tjrbiosciences.com
- Total disclosed funding: $21M
- Latest round: Series A (Apr 30, 2020)
- Investors on record: 5

## About

Established in 2014 based in Shenzhen, China, Shenzhen TargetRx, Inc. operates as an anti-cancer drug developer focusing on research, development, sales, and service of targeted drugs for cancer therapy. The company has more than 200 inventions patented in China, the USA, Europe, and Japan. The company's Founder, Chairman, and CEO, Yihan Wang, graduated from the Department of Chemistry of New York University. He is one of the co-founders of the Chinese American Biomedical Association (CABA). The company has partnerships with CCB International, Shenzhen Capital Group, Shenzhen Acacia Investment, and Shenzhen Leaguer Tsing-Yuan Venture Capital Management. In January 2025, it raised series C funding for USD 50 million.

The company's products can be categorized into the next-generation Bcr-Abl allosteric inhibitor TGRX-678 and the third-generation ALK inhibitor TGRX-326, which have both conducted the dosing of the first subject in Phase I studies. The TGRX-326 is used to treat non-small cell lung cancer (NSCLC). The TGRX-678 is used to treat chronic myelogenous leukemia (CML).

Shenzhen TargetRx, Inc. generates revenue by providing small - molecule targeted anti-cancer drugs to the pharmaceutical market and related R & D services to partners.

The company will use the series C funding for the advancement of overseas clinical studies of several innovative drugs.

## Funding rounds

- Series A, Apr 30, 2020, $21M — CCB International Asset Management, Oriental Fortune Capital, Tsing-Yuan Capital, Shenzhen Capital Real Estate Fund
- Angel, Jan 1, 2015 — Leaguer Angel

## Investors

- Leaguer Angel (https://capitalatlas.ai/funds/leaguer-angel) — Angel
- CCB International Asset Management (https://capitalatlas.ai/funds/ccb-international-asset-management) — Series A
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- Tsing-Yuan Capital (https://capitalatlas.ai/funds/tsing-yuan-capital) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A